Dulera 100 mcg 5 mcg inhaler?

Dulera 100 mcg/5 mcg Inhaler: Uses, Side Effects, and More

What is Dulera 100 mcg/5 mcg Inhaler Used For?

Dulera 100 mcg/5 mcg inhaler is a combination medication containing the active ingredients mometasone and formoterol. It is used to control asthma symptoms and improve lung function in patients with chronic obstructive pulmonary disease (COPD)[1]. Mometasone is an inhaled corticosteroid that reduces airway inflammation, while formoterol is a long-acting beta agonist that relaxes airway muscles to improve breathing[1].

How Does Dulera Work?

When inhaled, mometasone reduces inflammation in the airways by reducing the production of chemical mediators, such as histamine and leukotrienes. This helps to alleviate symptoms of asthma and COPD, such as wheezing, coughing, and shortness of breath. Formoterol helps to relax the airway muscles, making it easier to breathe and increasing lung function.

Side Effects of Dulera

Common side effects of Dulera include headaches, throat irritation, and upper respiratory tract infections[2]. More serious side effects, such as bronchospasm, hypokalemia, and increased intra-ocular pressure, can occur in rare cases.

Dulera vs. Other Inhalers

Dulera is different from other inhalers in that it contains both an inhaled corticosteroid and a long-acting beta agonist. This combination helps to control both inflammation and airway constriction, making it a more effective treatment for severe asthma and COPD[3]. Other inhalers, such as Advair (fluticasone and salmeterol) and Symbicort (budesonide and formoterol), also contain a combination of an inhaled corticosteroid and a long-acting beta agonist.

When Does Exclusivity Expire?

The patent for Dulera (mometasone furoate/formoterol fumarate) is held by Merck & Co. The drug was submitted to the FDA on April 24, 2007, and was approved on August 30, 2006. According to DrugPatentWatch.com, the patent for Dulera expires in 2026 [4]. This means that generic versions of the medication may be available after that date.

References

[1] Merck & Co. (2006). Dulera (mometasone furoate/formoterol fumarate) inhalation powder prescribing information.

[2] Dulera (mometasone furoate/formoterol fumarate) inhalation powder. (2022). MedlinePlus.

[3] Global Initiative for Asthma. (2020). Global Strategy for Asthma Management and Prevention.

[4] DrugPatentWatch.com. (2022). Dulera (mometasone furoate/formoterol fumarate) patents.